Evaluating the Efficacy and Safety of Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Authors

Keywords:

Autosomal dominant polycystic kidney disease (ADPKD), Tolvaptan, eGFR (estimated glomerular filtration rate), TKV (total kidney volume)

Abstract

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) causes end-stage renal disease (ESRD) and a decline in the estimated glomerular filtration rate (eGFR) (1,2). In this meta-analysis, we aimed to assess the efficacy and safety of tolvaptan in delaying both eGFR decline and total kidney volume (TKV) increase in patients with ADPKD.

METHODS: A systematic search was conducted on PubMed, EMBASE, Web of Science, and Cochrane databases from inception to July 2024. We used the relevant keywords to include studies reporting delay in both eGFR decline and total kidney volume (TKV) increase after tolvaptan therapy. The definition of delay in both eGFR decline and total kidney volume (TKV) increase was identified across the included studies. The number of patients who achieved delay in both eGFR decline and total kidney volume (TKV) increase were extracted from the included studies. Review Manager Version 5.4 (RevMan 5.4) was used for meta-analysis. The random effect model was used in the presence of heterogeneity.

RESULTS: 4 studies (3-6) with 1775 patients were included. The pooled mean difference showed that tolvaptan significantly delays eGFR decline [MD = 1.21, 95% CI (0.81, 1.62), P = 0.001, I² = 40%] and total kidney volume (TKV) increase [MD = -3.02%, 95% CI (-3.62%, -2.42%, P = 0.001, I² = 42%] compared to placebo in ADPKD patients. Furthermore, our pooled analysis demonstrated a significant difference in our secondary outcomes, in which tolvaptan reduced the likelihood of complications such as hypertension [OR = 0.87, 95% CI (0.72, 1.05)], hematuria [OR = 0.92, 95% CI (0.78, 1.09)], renal pain [OR = 0.89, 95% CI (0.75, 1.05)], and urinary tract infection [OR = 0.96, 95% CI (0.82, 1.12)]. However, tolvaptan-treated patients had increased adjusted odds of adverse effects, including polyuria [OR = 5.2, 95% CI (4.3, 6.3)], polydipsia [OR = 3.0, 95% CI (2.4, 3.8)], and hepatic injury [OR = 2.5, 95% CI (1.9, 3.3)].

CONCLUSION: Based on this meta-analysis, tolvaptan was associated with a significant delay in both eGFR decline and total kidney volume (TKV) increase. We observed a substantial reduction in the likelihood of complications such as hypertension, hematuria, renal pain, and urinary tract infection in ADPKD patients compared with placebo. However, a slightly higher risk of adverse effects such as polyuria, polydipsia, and hepatic injury was demonstrated. Additional randomized, large-volume clinical trials with long-term follow-ups are required, as tolvaptan may carry short and long-term prognostic implications.

Metrics

Metrics Loading ...

References

References

Wilson PD. Polycystic kidney disease. N Engl J Med. 2004;350:151–64, http://dx.doi.org/10.1056/NEJMra022161.

Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, et al. Mutations in GANAB, encoding the glucosidase II subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Human Genet.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med.

Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years’ experience. Clin J Am Soc Nephrol. 2011;6:2499–507.

Perrone RD, Chapman AB, Oberdhan D, Czerwiec FS, Sergeyeva O, Ouyang J, et al. The NOCTURNE randomized trial comparing 2 tolvaptan formulations. Kidney Int Rep. 2020;5:801–12, http://dx.doi.org/10.1016/j.ekir.2020.03.011.

Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, et al. Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial. Clin J Am Soc Nephrol. 2016;11:803–11, http://dx.doi.org/10.2215/CJN.06300615.

Downloads

Published

2025-01-01

How to Cite

Ibrahim, M., Hassan, I. N., & Abdulsamad, A. M. A. I. (2025). Evaluating the Efficacy and Safety of Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. International Journal of Medical Students, 12, S391. Retrieved from https://ijms.pitt.edu/IJMS/article/view/2968

Issue

Vol 12. (2024): Supplement 1

Section

Abstracts of the WCMSR

Categories

License

Copyright (c) 2024 Mohamed Ibrahim, Ibrahim Nagmeldin Hassan, Ahmed MohammedAlhassan Ismail Abdulsamad

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

  1. The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
  2. Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
  3. The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
    1. Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site; with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
    2. The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgment of its initial publication in this journal.
    3. Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
    4. Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
    5. The Author represents and warrants that:
      1. the Work is the Author’s original work;
      2. the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
      3. the Work is not pending review or under consideration by another publisher;
      4. the Work has not previously been published;
      5. the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
      6. the Work contains no libel, invasion of privacy, or other unlawful matter.
    6. The Author agrees to indemnify and hold Publisher harmless from the Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.

Enforcement of copyright

The IJMS takes the protection of copyright very seriously.

If the IJMS discovers that you have used its copyright materials in contravention of the license above, the IJMS may bring legal proceedings against you seeking reparation and an injunction to stop you using those materials. You could also be ordered to pay legal costs.

If you become aware of any use of the IJMS' copyright materials that contravenes or may contravene the license above, please report this by email to contact@ijms.org

 

Infringing material

If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to contact@ijms.org